RNAC Cartesian Therapeutics Inc

Price (delayed)

$16.85

Market cap

$299.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$56.1

Enterprise value

$206.9M

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic ...

Highlights
The company's equity has surged by 73% QoQ
The company's debt has shrunk by 72% YoY and by 4.5% QoQ
The quick ratio has soared by 133% QoQ but it is down by 42% YoY
RNAC's gross profit has shrunk by 69% YoY
RNAC's revenue has dropped by 69% year-on-year

Key stats

What are the main financial stats of RNAC
Market
Shares outstanding
17.8M
Market cap
$299.86M
Enterprise value
$206.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.99
Earnings
Revenue
$25.91M
EBIT
-$271.85M
EBITDA
-$269.18M
Free cash flow
-$58.99M
Per share
EPS
-$56.1
Free cash flow per share
-$10.9
Book value per share
-$21.64
Revenue per share
$4.78
TBVPS
$51.17
Balance sheet
Total assets
$325.21M
Total liabilities
$442.01M
Debt
$10.46M
Equity
-$116.8M
Working capital
$74.46M
Liquidity
Debt to equity
-0.09
Current ratio
3.03
Quick ratio
2.94
Net debt/EBITDA
0.35
Margins
EBITDA margin
-1,039%
Gross margin
100%
Net margin
-983.8%
Operating margin
-314.1%
Efficiency
Return on assets
-116.4%
Return on equity
N/A
Return on invested capital
-339.6%
Return on capital employed
-94.2%
Return on sales
-1,049.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNAC stock price

How has the Cartesian Therapeutics stock price performed over time
Intraday
4.27%
1 week
-5.97%
1 month
-26.1%
1 year
-51.58%
YTD
-18.53%
QTD
-37.62%

Financial performance

How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$25.91M
Gross profit
$25.91M
Operating income
-$81.38M
Net income
-$254.87M
Gross margin
100%
Net margin
-983.8%
RNAC's gross profit has shrunk by 69% YoY
RNAC's revenue has dropped by 69% year-on-year
The company's net margin fell by 16% QoQ
RNAC's net income is down by 16% from the previous quarter

Growth

What is Cartesian Therapeutics's growth rate over time

Valuation

What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.99
The company's EPS fell by 13% QoQ
The company's equity has surged by 73% QoQ
RNAC's P/S is 77% lower than its 5-year quarterly average of 15.1 and 14% lower than its last 4 quarters average of 4.1
RNAC's revenue has dropped by 69% year-on-year

Efficiency

How efficient is Cartesian Therapeutics business performance
Cartesian Therapeutics's ROIC has increased by 23% from the previous quarter
The company's return on sales fell by 16% QoQ
The return on assets has increased by 6% since the previous quarter

Dividends

What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNAC.

Financial health

How did Cartesian Therapeutics financials performed over time
Cartesian Therapeutics's total assets is 26% less than its total liabilities
The quick ratio has soared by 133% QoQ but it is down by 42% YoY
RNAC's current ratio has soared by 128% QoQ but it is down by 42% YoY
The company's debt is 109% higher than its equity
Cartesian Therapeutics's debt to equity has plunged by 118% YoY
The company's equity has surged by 73% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.